Skip to main content
SpringerLink
Log in

Phase II Study of Antineoplaston A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma

A Preliminary Report

  • Original Research Article
  • Published:
Drugs in R & D Aims and scope Submit manuscript

Abstract

Objective: A phase II study of antineoplaston A10 and AS2-1 was conducted to evaluate the antineoplastic activity in patients with recurrent diffuse intrinsic brain stem glioma.

Patients and methods: This report describes the results of treatment of the first 12 patients admitted to the study. Patients received escalating doses of antineoplaston A10 and AS2-1 by intravenous bolus injections. The median duration of treatment was 6 months and the average dosage of antineoplaston A10 was 11.3 g/kg/day and of antineoplaston AS2-1 0.4 g/kg/day. Responses were assessed by gadolinium-enhanced magnetic resonance imaging of the head.

Results: Of ten evaluable patients, complete response was determined in two cases (20%), partial response in three (30%), stable disease in three (30%) and progressive disease in two (20%). Survival at 2 years was 33.3%. Currently, of all 12 patients, two (17%) were alive and tumour free for over 5 years since initial diagnosis; one was alive for more than 5 years, and another for more than 4 years from the start of treatment. Only mild and moderate toxicities were observed, which included three cases of skin allergy, two cases of anaemia, fever and hypernatraemia, and single cases of agranulocytosis, hypoglycaemia, numbness, tiredness, myalgia and vomiting.

Conclusion: The results of this study compared favourably with the responses of patients treated with radiation therapy and chemotherapy. The study continues with accrual of additional patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma. In: Adam D, editor. Recent advances in chemotherapy. Munich: Futramed Publishers, 1992: 2506–7

    Google Scholar 

  2. Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 1998; 40: 265–71

    Article  PubMed  CAS  Google Scholar 

  3. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143–51

    Article  PubMed  CAS  Google Scholar 

  4. Adam L, Crépin M, Savin C, et al. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7 ras cells in vitro and in nude mice. Cancer Res 1995; 55: 5156–60

    PubMed  CAS  Google Scholar 

  5. Samid D, Shack S, Sherman LT. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 1992; 52: 1988–92

    PubMed  CAS  Google Scholar 

  6. Shack S, Chen LC, Miller AC, et al. Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Int J Cancer 1995; 63: 124–9

    Article  PubMed  CAS  Google Scholar 

  7. DiCroce L, Raker VA, Corsaro M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079–82

    Article  CAS  Google Scholar 

  8. Gorospe M, Shack S, Guyton KZ, et al. Up-regulation and functional role of p21WAF1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth Differ 1996; 7: 1609–15

    PubMed  CAS  Google Scholar 

  9. Liu L, Samid D. Mutant p53 as a target of phenylacetate in human glioblastoma [abstract 2580]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research, Toronto, Canada; AACR 1995, 433 433

    Google Scholar 

  10. Kamitani H, Tanjura S, Watanbe K, et al. Histone acetylation may suppress human glioma cell proliferation with p21WAF1/Cip1 and gelsolin are induced. Neuro-Oncol 2002; 4: 95–101

    PubMed  CAS  Google Scholar 

  11. Burzynski SR, Mohabbat MO, Lee SS. Preclinical studies of antineoplaston AS2-1 and antineoplaston AS2-5. Drugs Exp Clin Res 1986; 12 (Suppl 1): 11–6

    PubMed  CAS  Google Scholar 

  12. Ram Z, Samid D, Waldbridge S, et al. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 1994; 54: 2923–7

    PubMed  CAS  Google Scholar 

  13. Stockhammer G, Manley GT, Johnson R, et al. Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J Neurosurg 1995; 83: 672–81

    Article  PubMed  CAS  Google Scholar 

  14. Liu L, Shack S, Stetler-Stevenson WG, et al. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Dermatol 1994; 103: 355–40

    Article  Google Scholar 

  15. Danesi R, Nardini D, Basolo F, et al. Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacol 1996; 49: 972–9

    PubMed  CAS  Google Scholar 

  16. Sidell N, Wada R, Han G, et al. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int J Cancer 1995; 60: 507–14

    Article  PubMed  CAS  Google Scholar 

  17. Cinatl J, Cinatl JA, Herneiz P, et al. Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate. Cancer Lett 1994; 78: 41–8

    Article  PubMed  CAS  Google Scholar 

  18. Ferrandina G, Melichar B, Loercher A, et al. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res 1997; 57: 4309–15

    PubMed  CAS  Google Scholar 

  19. Samid D, Yeh A, Prasanna P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 1992; 809: 1576–81

    Google Scholar 

  20. Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res 1990; 16: 361–9

    PubMed  CAS  Google Scholar 

  21. Liau MC, Liau CP, Burzynski SR. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. Int J Exp Clin Chemother 1992; 5: 9–17

    Google Scholar 

  22. Tsuda H, Hara H, Eriguchi N, et al. Inhibitory effect of antineoplaston A10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines. Kurume Med J 1990; 37: 97–104

    Article  PubMed  CAS  Google Scholar 

  23. Wood JC, Copland JA, Muldoon TG, et al. 3-phenylacetylamino-2, 6-piperidinedione inhibition of rat Nb2 lymphoma cell mitogenesis. Proc Soc Exp Biol Med 1991; 197: 404–8

    PubMed  CAS  Google Scholar 

  24. Xu W, Yu R, Gao C, et al. The preliminary antitumor assay of antineoplaston A10 against the s180 and the effects of cAMP levels in tumor and liver tissues of mice. Adv Exp Clin Chemother 1988; 2: 41–4

    Google Scholar 

  25. Hashimoto K, Koga T, Shintomi Y, et al. The anticancer effect of antineoplaston A10 on human breast cancer serially transplanted to athymic mice. Nippon Gan Chiryo Gakkai Shi 1990; 25: 1–5

    PubMed  CAS  Google Scholar 

  26. Burzynski SR. Purified antineoplaston fractions and methods of treating neoplastic disease. US patent 4,470,970. 1984

    Google Scholar 

  27. Burzynski SR. Phase I clinical studies of antineoplaston AS2-5 injections. In: Ishigami J, editor. Recent advances in chemotherapy. Tokyo: University of Tokyo Press, 1985: 586–7

    Google Scholar 

  28. Burzynski SR. Potential of antineoplastons in diseases of old age. Drugs Aging 1995; 7: 157–67

    Article  PubMed  CAS  Google Scholar 

  29. Chang SM, Kuhn JG, Robins HI, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium Report. J Clin Oncol 1999; 17: 984–90

    PubMed  CAS  Google Scholar 

  30. Buckner JD, Malkin MG, Reed E, et al. Phase II study of antineoplaston A10 (NSC 648539) and AS2-1 (NSC 6200261) in patients with recurrent glioma. Mayo Clin Proc 1999; 74: 137–45

    Article  PubMed  CAS  Google Scholar 

  31. Burzynski SR. Efficacy of antineoplastons A10 and AS2-1. Mayo Clin Proc 1999; 74: 641–2

    Article  PubMed  CAS  Google Scholar 

  32. Fulton DS, Levin VA, Wara WM, et al. Chemotherapy of pediatric brain-stem tumors. J Neurosurg 1981; 54: 721–5

    Article  PubMed  CAS  Google Scholar 

  33. Rodriguez LA, Prados M, Fulton D, et al. Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. Neurosurgery 1988; 23: 691–3

    Article  Google Scholar 

  34. Allen JC, Hancock C, Walker R, et al. PCNU and recurrent childhood brain tumors. J Neurooncol 1987; 5: 241–4

    Article  PubMed  CAS  Google Scholar 

  35. van Eys J, Baram TZ, Cangir A, et al. Salvage chemotherapy for recurrent primary brain tumors in children. J Pediatr 1988; 113: 601–6

    Article  PubMed  Google Scholar 

  36. Prados M, Rodriguez L, Chamberlain M, et al. Treatment of recurrent gliomas with 1, 3-bis(2-chlorethyl)-1-nitrosourea and α-fluromethylornithine. Neurosurgery 1989; 24: 806–9

    Article  PubMed  CAS  Google Scholar 

  37. Heideman RL, Packer RJ, Reaman GH, et al. A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer 1993; 72: 271–5

    Article  PubMed  CAS  Google Scholar 

  38. Corden BJ, Strauss LC, Killmond T, et al. Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors. J Neurooncol 1991; 11: 57–63

    Article  PubMed  CAS  Google Scholar 

  39. Pendergrass TW, Milstein JM, Geyer JR, et al. Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol 1987; 5: 1221–31

    PubMed  CAS  Google Scholar 

  40. Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brain stem tumors: results of pediatric oncology group phase III trial comparing conventional vs hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 1999; 43: 959–64

    Article  PubMed  CAS  Google Scholar 

  41. Jennings MT, Sposto R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the children’s cancer group. J Clin Oncol 2002; 20 (16): 3431–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from California Age Research Institute. Antineoplaston A10 and AS2-1 were given free of charge.

The authors express their appreciation to Dr Dieter Schellinger and Dr Joshua Pleasure for evaluation of MRI films. We acknowledge the contribution of the following local co-investigators: Drs David Bigos, Arie Ashkenasi, Robert Steele, Joan B. Parkhurst, Jordan Wilbur, M.O. Tomeh, Matt W. Hemstreet, Luis A. Rodriguez, Theddore Cole, David Castellan, Chris Arth.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Burzynski Clinic, 9432 Old Katy Road, Houston, Texas, USA

    Stanislaw R. Burzynski, Robert A. Weaver & Barbara G. Szymkowski

  2. Department of Medical Oncology, Burzynski Clinic, Houston, Texas, USA

    Robert I. Lewy & Maxwell L. Axler

  3. Department of Medical Documentation and Data Processing, Burzynski Clinic, Houston, Texas, USA

    Tomasz J. Janicki & Jaroslaw K. Paszkowiak

  4. Department of Pediatric Oncology, Burzynski Clinic, Houston, Texas, USA

    Gabor F. Jurida & Mark Bestak

  5. Department of Radiology, Burzynski Clinic, Houston, Texas, USA

    Mohammad I. Khan

Authors
  1. Stanislaw R. Burzynski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert I. Lewy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert A. Weaver
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maxwell L. Axler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomasz J. Janicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gabor F. Jurida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jaroslaw K. Paszkowiak
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Barbara G. Szymkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mohammad I. Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mark Bestak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanislaw R. Burzynski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burzynski, S.R., Lewy, R.I., Weaver, R.A. et al. Phase II Study of Antineoplaston A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma. Drugs R&D 4, 91–101 (2003). https://doi.org/10.2165/00126839-200304020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304020-00002

Keywords

Search

Navigation